Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
Abstract The number of patients receiving sodium–glucose cotransporter 2 inhibitors (SGLT2is), especially those with heart failure, is increasing worldwide. SGLT2is control glycaemia by triggering glycosuria with simultaneous facilitation of a more ketogenic metabolic profile. Patients therefore are...
Main Authors: | Luka Cavka, Urska Bencak Ferko, Natasa Pitz, Zoranco Trpkovski, Mitja Lainscak |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13452 |
Similar Items
-
Closing anion gap without insulin in euglycaemic diabetic ketoacidosis
by: Resham Raj Poudel, et al.
Published: (2017-01-01) -
Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports
by: Margaret Pikovsky, et al.
Published: (2021-06-01) -
Euglycaemic Ketoacidosis Due to Extremely Low-Calorie Intake and Dehydration After Laparoscopic Sleeve Gastrectomy in a Patient with Type 2 Diabetes
by: Liu Z, et al.
Published: (2022-08-01) -
Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors - a report on two cases
by: Antonio Burgio, et al.
Published: (2018-11-01) -
Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)